Natac Natural Ingredients SA

Natac Natural Ingredients SA

BBME:NAT
0.59
EUR
+0.04
(+6.36%)
317.38MMarket Cap
Mar 03Next Earn
Natac Natural Ingredients SA
BME:NAT
(Spanish Stock Exchange)

Recent

price

0.59

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
0.03
0.04
0.05
0.06
0.06
0.03
0.02
0.07
0.05
0.05
0.59
0.06
0.08
- -
- -
Revenue per Share
- -
- -
- -
-0.42
-0.01
0.1
-0.06
0.02
0.03
- -
0.03
0.02
- -
- -
- -
Basic EPS, GAAP
0.02
0.01
-0.01
-0.88
0.01
0.11
-0.05
-0.02
-0.03
-0.01
-0.25
- -
-0.01
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.06
- -
- -
- -
- -
0.1
- -
- -
- -
Dividend per Share
1.49
2
1.99
1.57
1.56
1.65
1.53
1.82
1.87
-0.75
-0.45
0.1
0.1
- -
- -
Book Value per Share
1.49
1.96
1.96
1.54
1.53
1.63
1.51
-0.1
0.15
-0.89
-0.82
-0.04
-0.05
- -
- -
Tangible Book Value per Share
4
4
4
4
4
4
4
20
22
23
38
418
432
432
432
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
1
1
1
22
27
36
- -
- -
Sales/Revenue/Turnover
18.39
30.28
7.61
-11.17
8.35
-72.51
-137.03
2.02
-28.65
-8.52
9.82
11.75
12.91
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4
5
5
- -
- -
Depreciation Expense
- -
- -
- -
-2
- -
- -
- -
- -
1
- -
1
6
- -
- -
- -
Net Income, GAAP
30
- -
- -
- -
- -
- -
- -
2.57
- -
29.07
53.42
25.89
- -
- -
- -
Effective Tax Rate (%)
3.88
11.16
-8.39
-756.35
-24.57
295.74
-280.94
23.33
59.23
7.59
4.27
24.15
1.11
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
3
6
-1
- -
-2
-3
-2
-14
- -
- -
Working Capital
1
1
1
- -
- -
- -
- -
4
- -
6
19
47
47
- -
- -
LT Debt
6
8
8
6
6
7
6
37
42
-17
-16
44
43
- -
- -
Total Equity
- -
0.37
- -
- -
- -
5.93
- -
1.95
- -
-0.27
-2.05
3.01
- -
- -
- -
Return on Invested Capital (%)
- -
0.38
- -
- -
- -
5.99
- -
1.73
- -
0.65
10.63
13.28
- -
- -
- -
Return on Capital (%)
- -
0.25
-0.22
-23.73
-0.91
6.18
-3.79
1.56
1.56
- -
- -
- -
0.94
- -
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
33
44
- -
LT Borrowings
47
44
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
432
432
432
Market Capitalization
296
317
345

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
28
31
- -
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
4
6
- -
Inventories
19
19
- -
Total Current Liabilities
43
53
- -
Payables & Accruals
- -
- -
- -
ST Debt
33
44
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
27
2024
- -
- -
36
2025
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.02
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.1
2024
- -
- -
- -
2025
- -
- -
- -
Business
Iffe Futura, S.A., now operating under the name Natac Natural Ingredients, S.A., is a Spain-based company specializing in the research, development, production, and marketing of natural ingredients focused primarily on plant extracts and Omega-3 oils. The company’s core product portfolio includes sustainable botanical extracts and high-quality Omega-3 fatty acids, which serve diverse sectors such as functional foods, nutritional supplements, pharmaceuticals, cosmetics, and animal nutrition. Founded and headquartered in Oleiros, La Coruña, Spain, Iffe Futura has positioned itself as a leading operator in natural ingredients with advanced development and refinement capabilities, particularly emphasizing innovative plant-derived and marine-based active compounds. In a major strategic development in 2023, Iffe Futura completed a reverse merger with Natac, creating a larger group that synergistically combines the strengths of both entities. This merger expanded their portfolio and geographic presence, consolidating research and production facilities including sites in Córdoba and Hervás for plant extracts and in As Somozas, Galicia, for Omega-3 production. Recently, the company secured €18 million financing led by Inveready and attracted strategic partnerships including NATAC Group as a minority shareholder in its Omega-3 production subsidiary, IFFE BIOTECH, bolstering capacity and market reach. Additionally, in late 2025, Iffe Futura signed a €20 million equity commitment with LDA Capital to support its strategic growth plan amid challenging market conditions. Iffe Futura operates primarily through two divisions: Plant Extracts, focused on developing a broad range of natural extracts from botanicals with proven health benefits; and Omega-3, dedicated to manufacturing premium quality Omega-3 oils with a production capacity exceeding 10,000 tons per year at its Galicia facility. The company has a dedicated R&D focus on sustainable, industrially viable projects that leverage scientific knowledge to create high-performance ingredients. Its products target B2B markets including functional food companies and pharmaceutical industries across Spain and broader European markets, aiming to capitalize on growing demand for natural and health-enhancing ingredients. The company remains listed on BME Growth, with its evolution marked by continuous innovation in natural ingredient production and strategic financial partnerships that underpin its expansion. The merger with Natac and subsequent investments have positioned Natac Natural Ingredients as a significant player in the European natural extracts and Omega-3 oil markets, focusing on sustainability, quality, and industrial viability. This strategic expansion reflects a broader trend towards health-oriented natural product solutions with robust research, production, and marketing capabilities across several countries in Europe.